The aim is to investigate the effects of wet and dry cupping on blood levels in normal people
Conditions
Interventions
Wet Cupping therapy OR Dry Cupping Therapy
Dry Cupping Therapy OR Wet Cupping Therapy
Sponsors
Durban University of Technology
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Inclusion criteria: Any healthy male participant between 20-45 years of age, who resides in the eThekwini municipality for the duration of the study and who does not have any characteristics described under the exclusion criteria. For the purposes of this study a healthy male participants will be defined as having: 1. Normal blood pressure (Systolic pressure between 140mmHg and 120 mmHg and Diastolic pressure between 70mmHg and 90mmHg). This will be measured using a Welch Allen Sphygmomanometer on the left arm. 2. Heart Rate of between 50 beats per minute up to 90 beats per minute. This will be measured using manual palpation of radial pulse for 60 seconds. 3. Respiratory rate of between 12 breaths per minute and 25 breaths per minute. This will be measured by counting manually for 60 seconds. 4. Temperature (36.5°C to 37.3°C); average (37°C). This will be measured using a standard mercury oral thermometer. The above vital signs are the standard in classifying healthy participants in that any deviation from the normal ranges of blood pressure, heart rate, respiratory function or temperature can allude to systemic disease and the participant will therefore not be eligible to take part in the study (Pasqualetti et al. 2010; Gori, Breithaupt-Groegler et al. 2017).
Exclusion criteria
Exclusion criteria: Exclusion Criteria: Any participant who has any of the following characteristics will not be included in the study. • Falls out of the age range (20-45) at their last birthday. • Has any known systemic illness which is active or dormant. • On anticoagulant or anti-platelet medication (Warfarin or Aspirin). • Has a bleeding disorder or blood dyscrasia. • Who is known to be anaemic due to any cause. • Who has had cupping therapy done (either dry or wet) within two months previous to the study. • Who declines consent and does not wish to follow-through with the study protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Full Blood Count, Erythrocyte Sedimentation Rate, C-Reactive Protein, Cortisol,Interleukin 6, Interleukin 10, Transforming Growth Factor Beta (TGF-ß) and Tumour Necrosis Factor Alpha (TNF-a) | — |
Secondary
| Measure | Time frame |
|---|---|
| Full Blood Count, Erythrocyte Sedimentation Rate, C-Reactive Protein, Cortisol,Interleukin 6, Interleukin 10, Transforming Growth Factor Beta (TGF-ß) and Tumour Necrosis Factor Alpha (TNF-a) | — |
Countries
South Africa
Contacts
Public ContactLavisha Deonarain
Institutional Research Ethics Administrator
Outcome results
None listed